Regeneron Pharmaceuticals Income from Continuous Operations 2010-2024 | REGN

Regeneron Pharmaceuticals income from continuous operations for the twelve months ending September 30, 2024 was $4.655B, a 16.62% increase year-over-year.

  • Regeneron Pharmaceuticals annual income from continuous operations for 2023 was $3.954B, a 8.87% decline from 2022.
  • Regeneron Pharmaceuticals annual income from continuous operations for 2022 was $4.338B, a 46.28% decline from 2021.
  • Regeneron Pharmaceuticals annual income from continuous operations for 2021 was $8.075B, a 129.86% increase from 2020.

Regeneron Pharmaceuticals Income from Continuous Operations 2010-2024 | REGN

  • Regeneron Pharmaceuticals annual income from continuous operations for 2023 was $3.954B, a 8.87% decline from 2022.
  • Regeneron Pharmaceuticals annual income from continuous operations for 2022 was $4.338B, a 46.28% decline from 2021.
  • Regeneron Pharmaceuticals annual income from continuous operations for 2021 was $8.075B, a 129.86% increase from 2020.